Changes of metabolic parameters in patients with primary hyperparathyroidism of different age groups

BACKGROUND: Studies have shown a high incidence of metabolic disorders and cardiovascular diseases in patients with primary hyperparathyroidism (PHPT). PHPT is usually diagnosed in people of age over 50 years and therefore age-associated changes of metabolism should be excluded. Researching predictors of cardiovascular pathology contributes to choosing optimal approaches to personalized patient management.

AIM: To determine the features of metabolic disorders in patients of various age groups with confirmed active stage of PHPT.

MATERIALS AND METHODS: A single-center observational retrospective comparative study of patients with active PHPT at the age of 18-49 years (Group 1, n=66) and over 50 years (Group 2, n=290) was carried out. The exclusion criteria for both groups were: persistent PHPT or recurrence after surgical treatment of the disease in history; clinical/genetically confirmed multiple endocrine neoplasia syndrome; for Group 1 — pregnancy, lactation. The assessment of laboratory parameters of mineral, carbohydrate, fat and purine metabolism obtained during a hospital examination was carried out, the frequencies of various metabolic disorders were determined and compared between age groups.

RESULTS: There were no significant differences in parathyroid hormone and serum calcium levels between age groups, however, there were more severe hypercalciuria, a tendency to active bone metabolism and lower vitamin D level in Group 1. Patients of Group 2 had statistically significantly lower glomerular filtration rate and a higher frequency of bone complications. In the same group glycaemia and triglycerides levels were higher (the latter difference has the level of a statistical tendency). These patients also had a higher body mass index and, as a result, a higher incidence of obesity (37% vs 20%, p=0.006) and diabetes mellitus type 2 (12.5% vs 3%, p=0.013). At the same time, patients did not significantly differ in the rates of hypercholesterolemia (62% in Group 1 vs 70% in Group 2, p=0.228), hypertriglyceridemia (27% vs 32%, p=0.433) and hyperuricemia (42% vs 50%, p=0.302), significantly exceeding similar indicators in the general Russian population.

CONCLUSION: Carbohydrate disorders are more often observed in patients older than 50 years, providing an increased prevalence of diabetes mellitus type 2 among patients with PHPT compared with the general population. The high incidence of various types of dyslipidemia and hyperuricemia in the primary parathyroid pathology has no age specific features. Thereby these disorders are significant risk factors of cardiovascular diseases, even in young people with PHPT.

1. Corbetta S, Mantovani G, Spada A. Metabolic Syndrome in Parathyroid Diseases. Front Horm Res. 2018;49:67-84. doi: https://doi.org/10.1159/000486003

2. Procopio M, Barale M, Bertaina S, et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine. 2014;47(2):581–589. doi: https://doi.org/10.1007/s12020-013-0091-z

3. Bibik EE, Eremkina AK, Krupinova JA, et al. Impaired glucose metabolism and other metabolic disorders in patients with primary hyperparathyroidism. Diabetes mellitus. 2020;23(5):459-466. (In Russ.). doi: https://doi.org/10.14341/DM12436

4. Mokrysheva NG. Okoloshitovodnye zhelezy. Pervichnyi giperparatireoz. Moscow: OOO «Meditsinskoe informatsionnoe agenstvo»; 2019 (In Russ.).

5. Babinsky VN, Hannan FM, Ramracheya RD, et al. Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy. Endocrinology. 2017;158(8):2486-2502. doi: https://doi.org/10.1210/en.2017-00111

6. Reis JP, Selvin E, Pankow JS, et al. Parathyroid hormone is associated with incident diabetes in white, but not black adults: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Metab. 2016;42(3):162-169. doi: https://doi.org/10.1016/j.diabet.2015.12.004

7. Kanazawa I. Interaction between bone and glucose metabolism [Review]. Endocr J. 2017;64(11):1043-1053. doi: https://doi.org/10.1507/endocrj.EJ17-0323

8. Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. (In Russ.). doi: https://doi.org/10.14341/probl12801

9. Shah VN, Bhadada SK, Bhansali A, et al. Influence of age and gender on presentation of symptomatic primary hyperparathyroidism. J Postgrad Med. 2012;58(2):107-111. doi: https://doi.org/10.4103/0022-3859.97171

10. Jovanovic M, Paunovic I, Zdravkovic V, et al. Case-control study of primary hyperparathyroidism in juvenile vs. adult patients. Int J Pediatr Otorhinolaryngol. 2020;131:109895. doi: https://doi.org/10.1016/j.ijporl.2020.109895

11. van Wijk JPH, Dreijerink KMA, Pieterman CRC, et al. Increased prevalence of impaired fasting glucose in MEN1 gene mutation carriers. Clin Endocrinol (Oxf ). 2012;76(1):67-71. doi: https://doi.org/10.1111/j.1365-2265.2011.04166.x

12. Castellano E, Attanasio R, Boriano A, Borretta G. Clinical Presentation of Primary Hyperparathyroidism in Older Adults. J Endocr Soc. 2019;3(12):2305-2312. doi: https://doi.org/10.1210/js.2019-00316

13. Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes mellitus. 2016;19(2):104-112. (In Russ.). doi: https://doi.org/10.14341/DM2004116-17

14. Mokrysheva NG, Dobreva EA, Mirnaya SS, Dedov II. Carbohydrate and lipid metabolism disorders in women with primary hyperparathyroidism: results of cross-sectional study. Diabetes mellitus. 2019;22(1):8-13. (In Russ.). doi: https://doi.org/10.14341/DM9450

15. Bao Y, Ma X, Yang R, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab. 2013;98(1):345-351. doi: https://doi.org/10.1210/jc.2012-2906

16. Gianotti L, Piovesan A, Croce CG, et al. Interplay between serum osteocalcin and insulin sensitivity in primary hyperparathyroidism. Calcif Tissue Int. 2011;88(3):231-237. doi: https://doi.org/10.1007/s00223-010-9453-1

17. Dedov II, Shestakova MV, Mayorov AY, et al. Diabetes mellitus type 2 in adults. Diabetes mellitus. 2020;23(2S):4-102. (In Russ.). doi: https://doi.org/10.14341/DM12507

18. Tassone F, Procopio M, Gianotti L, et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet Med. 2009;26(10):968–973. doi: https://doi.org/10.1111/j.1464-5491.2009.02804.x

19. Bibik EE, Dobreva EA, Ajnetdinova AR, et al. Metabolic features of young patients with primary hyperparathyroidism. Obesity and metabolism. 2021;18(3):236-244. (In Russ.). doi: https://doi.org/10.14341/omet12771

20. Zhernakova YV, Zheleznova EA, Chazova IE, et al. The prevalence of abdominal obesity and the association with socioeconomic status in Regions of the Russian Federation, the results of the epidemiological study — ESSE-RF. Terapevticheskii arkhiv. 2018;90(10):14-22 (In Russ.). doi: https://doi.org/10.26442/terarkh201890104-22

21. Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Profilakticheskaya Meditsina. 2016;19(1):15?23. (In Russ.). doi: https://doi.org/10.17116/profmed201619115-23

22. Grethen E, Hill KM, Jones R, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab. 2012;97(5):1655-1662. doi: https://doi.org/10.1210/jc.2011-2280

23. Ponvilawan B, Charoenngam N, Ungprasert P. Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis. Int J Rheum Dis. 2020;23(2):174-180. doi: https://doi.org/10.1111/1756-185X.13740

24. Shalnova SA, Deev AD, Artamonov G V, et al. Hyperuricemia and its correlates in the russian population (results of ESSE-RF epidemiological study). Ration Pharmacother Cardiol. 2015;10(2):153-159 (In Russ.). doi: https://doi.org/10.20996/1819-6446-2014-10-2-153-159

25. Sugimoto R, Watanabe H, Ikegami K, et al. Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 2017;91(3):658-670. doi: https://doi.org/10.1016/j.kint.2016.09.041